A detailed history of First Republic Investment Management, Inc. transactions in Incyte Corp stock. As of the latest transaction made, First Republic Investment Management, Inc. holds 3,928 shares of INCY stock, worth $281,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,928
Previous 4,036 2.68%
Holding current value
$281,716
Previous $251,000 9.96%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

SELL
$57.77 - $65.93 $6,239 - $7,120
-108 Reduced 2.68%
3,928 $226,000
Q2 2023

Jul 28, 2023

SELL
$60.95 - $75.51 $304 - $377
-5 Reduced 0.12%
4,036 $251,000
Q1 2023

May 11, 2023

BUY
$70.23 - $86.01 $4,775 - $5,848
68 Added 1.71%
4,041 $292,000
Q4 2022

Feb 13, 2023

BUY
$67.18 - $84.11 $2,955 - $3,700
44 Added 1.12%
3,973 $319,000
Q3 2022

Nov 03, 2022

SELL
$66.18 - $82.86 $38,516 - $48,224
-582 Reduced 12.9%
3,929 $262,000
Q2 2022

Aug 16, 2022

SELL
$66.18 - $83.18 $5,228 - $6,571
-79 Reduced 1.72%
4,511 $343,000
Q1 2022

May 16, 2022

BUY
$66.02 - $79.71 $396 - $478
6 Added 0.13%
4,590 $365,000
Q4 2021

Feb 09, 2022

BUY
$63.34 - $74.11 $54,409 - $63,660
859 Added 23.06%
4,584 $336,000
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $9,751 - $11,930
142 Added 3.96%
3,725 $256,000
Q2 2021

Aug 16, 2021

BUY
$79.87 - $87.53 $47,283 - $51,817
592 Added 19.79%
3,583 $301,000
Q1 2021

May 14, 2021

BUY
$76.02 - $100.5 $227,375 - $300,595
2,991 New
2,991 $243,000
Q4 2018

Feb 12, 2019

SELL
$58.5 - $69.94 $196,911 - $235,418
-3,366 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$61.75 - $74.23 $207,850 - $249,858
3,366 New
3,366 $233,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.